Dimopoulos, M. A., Beksac, M., Delimpasi, S., Vorobyev, V. I., Quach, H., Špička, I., Radocha, J., Robak, P., Kim, K., Cavo, M., Zafar, S. F., Moore, A., Morris, K., Polinkovsky, M., Brock, K., Grams, J., Manasanch, E., Mateos, M., Trudel, S. (2026). Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7565